Currently Viewing:
American Society of Hematology
Dr Thomas LeBlanc on the Importance of Shared Decision Making in Cancer Care
April 18, 2018
Dr Stephen Schuster: Unique CAR T Toxicities Require Provider Education
April 17, 2018
Dr Derek Raghavan Addresses the Concept of "Cookbook Medicine"
April 09, 2018
Dr Nina Shah Outlines New Treatments Being Studied for Multiple Myeloma
April 07, 2018
Dr Thomas LeBlanc: How to Increase Palliative Care Among Patients With Blood Cancer
April 02, 2018
Dr Thomas LeBlanc on Improving End-of-Life Outcomes for Patients With Blood Cancer
March 21, 2018
Dr Thomas LeBlanc: Patients With Blood Cancer and Palliative Care
March 10, 2018
Julie Wolfson: Supporting AYAs Before and After Treatment
January 14, 2018
Dr Julie Wolfson on What Clinicians Need to Understand About Adolescents/Young Adults With ALL
December 30, 2017
Dr Nina Shah on the Impact of New Treatments for Multiple Myeloma
December 29, 2017
Dr Stephen Schuster on Institution Commitments to Deliver CAR T Therapies
December 28, 2017
Currently Reading
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25, 2017
Dr Derek Raghavan: Ensuring Guidelines Are Implemented and Followed
December 22, 2017
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 18, 2017
Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs
December 18, 2017
Diagnosing Non-Chemotherapy Drug-Induced Neutropenia
December 16, 2017
Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma
December 12, 2017
New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study
December 12, 2017
Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children
December 12, 2017

Dr Shannon Maude Discusses Side Effects of CAR T Therapies

Most primary side effects of CAR T therapies occur early on after treatment and resolve quickly, but there are some that require long-term monitoring, explained Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.


Most primary side effects of CAR T therapies occur early on after treatment and resolve quickly, but there are some that require long-term monitoring, explained Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.

What side effects of CAR T therapies are currently known?

Primary side effects of CAR T therapies occur early on after treatment and they’re related to the growth of the T cells and the actual activity of the T cells. So many patients will have fever and potentially progressing to more serious symptoms requiring hospital-level care and sometimes ICU-level care. Those symptoms typically resolve within the first week or sometimes within the first several weeks.

The main side effects of this therapy are within the first 28 days. But there’s lots of monitoring and potential for long-term side effects as well. Most patients are usually physically very well after the first month of treatment, but still require some focused monitoring for some of the on-target effects of CAR T cells, which involve B-cell aplasia. So, these patients, because of how CD19 CAR T cells work, will be depleted of their normal B cells, and that requires monitoring and replacement of the immunoglobulin long term.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!